(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation

Nuclear Medicine and Biology

Volumn 30, Issue 7, 2003, Pages 747-751

  Luurtsema, G ^a   Molthoff, C F M ^a   Windhorst, A D ^a   Smit, J W ^b   Keizer, H ^c   Boellaard, R ^a   Lammertsma, A A ^a   Franssen, E J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

BBB; C 11 verapamil; Enantiomers; P gp

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN P; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11; ALCOHOL DEHYDROGENASE; CARBON; DIAGNOSTIC AGENT; KETOL ACID REDUCTOISOMERASE; RADIOPHARMACEUTICAL AGENT; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ENANTIOMER; EVALUATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; MEASUREMENT; MODEL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RADIOISOTOPE DISTRIBUTION; STEREOCHEMISTRY; TESTIS; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ISOMERISM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SWINE; TISSUE DISTRIBUTION; VALIDATION STUDY;

ALCOHOL OXIDOREDUCTASES; ANIMALS; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; ISOMERISM; KETOL-ACID REDUCTOISOMERASE; LLC-PK1 CELLS; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; ORGAN SPECIFICITY; P-GLYCOPROTEIN; PROTEIN TRANSPORT; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SWINE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; VERAPAMIL;

EID: 0141671728     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00078-7     Document Type: Article

References (31)

1. de Lange E.C., Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting implications of the barriers between blood and brain . Clin Pharmacokinet. 41:2002;691-703.
2. Taylor E.M. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet. 41:2002;81-92.
3. Stouch T.R., Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev. 54:2002;315-328.
4. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom J., Reiner P.B. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 76:2001;1121-1128.
5. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non- demented humans. Pharmacogenetics. 12:2002;535-541.
6. Elsinga P.H., Franssen E.J., Hendrikse N.H., Fluks L., Weemaes A.M., van der Graaf W.T., de Vries E.G., Visser G.M., Vaalburg W. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med. 37:1996;1571-1575.
7. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., van der Graaf W.T., Willemsen A.T., Vaalburg W., Franssen E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol. 124:1998;1413-1418.
8. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., Vaalburg W., Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 59:1999;2411-2416.
9. Doze P., Elsinga P.H., Maas B., van Waarde A., Wegman T., Vaalburg W. Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET. Neurochem Intern. 40:2002;145-155.
10. Levchenko A., Mehta B.M., Lee J.B., Humm J.L., Augensen F., Squire O., Kothari P.J., Finn J.D., Leonard E.F., Larson S.M. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med. 41:2000;493-501.
11. Lewis J.S., Dearling J.L., Sosabowski J.K., Zweit J., Carnochan P., Kelland L.R., Coley H.M., Blower P.M. Copper bis(diphosphine) complexes radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET . Eur J Nucl Med. 27:2000;638-646.
12. Sharma V., Beatty A., Wey S.P., Dahlheimer J., Pica C.M., Crankshaw C.L., Bass L., Green M.A., Welch M.J., Piwnica-Worms D. Novel gallium(III) complexes transported by MDR1 P-glycoprotein potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo . Chem Biol. 7:2000;335-343.
13. Kroemer H.K., Gautier J.C., Beaune P., Henderson C., Wolf C.R., Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 348:1993;332-337.
14. Stagni G., Gillespie W.R. Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography. J Chromatography B Biomedical Applications. 667:1995;349-354.
15. Echizen H., Vogelgesang B., Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther. 38:1985;71-76.
16. Echizen H., Brecht T., Niedergesass S., Vogelgesang B., Eichelbaum M. The effect of dextro-, levo-. and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 109:1985;210-217.
17. Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique . Br J Clin Pharmacol. 18:1984;733-740.
18. Mehvar R., Reynolds J.M., Robinson M.A., Longstreth J.A. Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers. Pharm Res. 11:1994;1815-1819.
19. Robinson M.A., Mehvar R. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes the role of plasma protein binding . Biopharm Drug Dispos. 17:1996;577-587.
20. Waldegger S., Niemeyer G., Morike K., Wagner C.A., Suessbrich H., Busch A.E., Lang F., Eichelbaum M. Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes. Cell Physiol Biochem. 9:1999;81-89.
21. Laberge P., Martineau P., Sebajang H., Lalonde G. Verapamil intoxication after substitution of immediate-release for extended-release verapamil. Am J Health Syst Pharm. 58:2001;402-405.
22. Karim A., Piergies A. Verapamil stereoisomerism enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both . Clin Pharmacol Ther. 58:1995;174-184.
23. Faude F., Enzmann V., Poschmann E., Hoffmann S., Wiedemann P. R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction. Graefes Arch Clin Exp Ophthalmol. 238:2000;537-541.
24. Eichelbaum M.F., Mikus M.G., Vogelgesang B.L. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 17:1984;453-458.
25. Murthy S.S., Nelson J., Power J.M. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug metab Dispos. 19:1991;1093-1100.
26. Bhatti M.M., Foster R.T. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. Biopharm Drug Dispos. 18:1997;387-396.
27. Luurtsema G., Windhorst A.D., Mooijer M.P., Herscheid J.D., Lammertsma A.A., Franssen E.J. Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring the P-glycoprotein function with positron emission tomography. J Labelled Compds Radiopharm. 45:2002;1199-1207.
28. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
29. Molthoff C.F., Pinedo H.M., Schluper H.M., Boven E. Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice. Cancer Immunol Immunother. 34:1991;191-197.
30. Boellaard R., Buijs F., de Jong H.W., Lenox M., Gremilion T., Lammertsma A.A. Characteristics of a single LSO crystal layer high resolution research tomograph PET scanner. Phys Med Biol. 48:2003;429-448.
31. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 97:1996;2517-2524.